Michael Roehrle

ClinOps Germany, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany

JCP
BI 1358894 in Patients With Inadequate Antidepressant Response
Original Research

September 3, 2025

No differences were observed between BI 1358894 treatment groups and placebo for primary and secondary endpoints. BI 1358894 was well tolerated with no increase in self-harm or suicidality.
, , , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe